ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1623

Serum Biomarkers Signature Identifies Patients with Overt B-Cell Non-Hodgkin Lymphoma Associated with Mixed Cryoglobulinemia in Chronic HCV Infection

Benjamin Terrier1, Wahiba Chaara2, Guillaume Geri3, David Saadoun4, Michelle Rosenzwajg Sr.5, Damien Sene Sr.6, Adrien Six2, David Klatzmann Sr.5 and Patrice Cacoub Sr.7, 1Internal Medicine, Cochin University Hospital, Paris, France, 2Laboratory I3 “Immunology, Immunopathology, Immunotherapy”, UMR CNRS 7211, INSERM U959, Groupe Hospitalier Pitié-Salpetrière, Paris, France, 3Intensive Care Unit, Cochin Hospital, Paris, France, 4Groupe Hospitalier Pitié Salpétrière, Service de Médecine Interne, DHU i2B, Paris, France, 5Laboratory I3 “Immunology, Immunopathology, Immunotherapy”, UMR CNRS 7211, INSERM U959, Paris, France, 6Department of Internal Medicine; 5 P3S post-genomic plateform, Groupe Hospitalier Pitié-Salpétrière, Université Pierre et Marie Curie, Paris, France, 7Department of Internal Medicine 2., CHU Pitié-Salpêtrière, Paris, France

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Biomarkers, Cryoglobulinemia, hepatitis and malignancy

  • Tweet
  • Email
  • Print
Session Information

Title: Infection-related Rheumatic Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: Hepatitis C virus (HCV) is associated with B-cell disorders, including mixed cryoglobulinemia (MC) and B-cell non-Hodgkin lymphoma (B-NHL). Early diagnosis of B-NHL in HCV-infected patients, in particular those with MC vasculitis, is critical to determine the optimal therapeutic management.

Aim: We hypothesized that combination of serum biomarkers could be used to identify B-NHL associated with MC in patients with chronic HCV infection.

Methods: 155 HCV infected patients have been included [median age 62 (31-85) years, M/F 70/85], with and without MC and/or B-NHL [57 patients without MC, 17 patients with asymptomatic MC, 62 patients with MC vasculitis, and 19 patients with MC vasculitis and B-NHL]. We measured serum levels of 8 markers previously described to be increased in patients with B-NHL i.e. soluble CD22, soluble CD27, soluble IL-2Ra, soluble CD137, free-light chains of immunoglobulins, heavy chains of immunoglobulins, gammaglobulins and C4 complement fraction. We used a multiparametric analysis in order to determine a signature that identifies patients with overt B-NHL associated with MC in chronic HCV infection.

Results: Serum levels were significantly different between patients without MC, patients with asymptomatic MC, patients with MC vasculitis and those with MC vasculitis and B-NHL: soluble CD22 (6.7 vs. 11.9 vs. 20.8 vs. 36.4 ng/ml, P<0.0001), soluble CD27 (71.9 vs. 75.7 vs. 122.9 vs. 263.9 U/ml, P<0.0001), soluble IL-2Ra (877 vs. 1035 vs. 2206 vs. 4044 pg/ml, P<0.0001), soluble CD137 (296 vs. 426 vs. 539 vs. 763 pg/ml, P<0.0001), free-light chains of immunoglobulins (ratio k/l 1.13 vs. 1.08 vs. 1.79 vs. 3.01, P<0.0001), heavy chains of immunoglobulins (ratio IgMk/IgMl 1.90 vs. 1.85 vs. 4.85 vs. 31.3, P<0.0001), gammaglobulins (14.1 vs. 17.0 vs. 12.1 vs. 6.0 g/l, P<0.0001) and C4 complement fraction (0.23 vs. 0.16 vs. 0.07 vs. 0.04 g/l, P<0.0001).

Using multiparametric analysis, we identified a signature involving soluble CD27, soluble IL-2Rα, gammaglobulins and C4 levels associated with the presence of overt B-NHL in HCV-infected patients. This signature had a sensitivity of 100%, a specificity of 63%, and positive and negative predictive values of 94 and 100% for discriminating patients with overt B-NHL and those without B-NHL.  

Conclusion: Overall, our data indicate that serum biomarkers signature allows identifying patients presenting with overt B-NHL associated with mixed cryoglobulinemia vasculitis in chronic HCV infection, and requiring invasive explorations in order to demonstrate the presence of malignant lymphoma.


Disclosure:

B. Terrier,
None;

W. Chaara,
None;

G. Geri,
None;

D. Saadoun,
None;

M. Rosenzwajg Sr.,
None;

D. Sene Sr.,
None;

A. Six,
None;

D. Klatzmann Sr.,
None;

P. Cacoub Sr.,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-biomarkers-signature-identifies-patients-with-overt-b-cell-non-hodgkin-lymphoma-associated-with-mixed-cryoglobulinemia-in-chronic-hcv-infection/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology